Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
By M. Ratain, T. Eisen, W. Stadler, K. Flaherty, S. Kaye, Gary Rosner, M. Gore, A. Desai, A. Patnaik, H. Xiong and 6 more. Journal of Clinical Oncology, 2006
960 citations recorded by the source corpus.
Subfields: Molecular Biology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1344a3ba8403fa7c201736fa6695c0bc0fb9678e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pathology and Forensic Medicine
Citations in the corpus
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (2006, methodology): “This methodology has been fully described previously (Ratain et al, 2006).”
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006, background): “These two randomized controlled trials confirmed sorafenib's activity against RCC by showing that it significantly prolonged progression-free survival (PFS) compared with placebo in patients with advanced diseas”
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (2008, background): “Sorafenib has shown an advantage compared with placebo in phase II/III clinical trials in patients with treatmentrefractory metastatic RCC, prolonging progression-free survival by 2- to 4-fold (61, 62).”